tbuckley/cabot-search huggingface dataset:
SAT0345 Histopathological Differences between Single-Organ Cutaneous Small Vessel Vasculitis and Other Cutaneous Vasculitis Associated with Systemic Involvement:
Authors: C. Fernández-Díaz, J. Loricera, C. González-Vela, R. Blanco, J.L. Hernández, M.A. González-Lόpez, S. Armesto, W. Salcedo, M. Marcellán, M. Lόpez-Escobar, M. Lacalle-Calderόn, V. Calvo-Río, F. Ortiz-Sanjuán, S. Hermana-Ramírez, M.Ά. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cutaneous vasculitis (CV) encompasses a wide and heterogeneous group of disorders characterized by the presence of necrotizing inflammatory lesions in the cutaneous blood vessels. Single-organ cutaneous small vessel vasculitis (SoCSVV) is, according to 2012 Chapel-Hill criteria, a vasculitis confined to the skin. <h3>Objectives</h3> Our aim was to compare the histopathological findings of skin biopsies from patients with SoCSVV and those with systemic involvement. <h3>Methods</h3> From a series of patients with CV, we selected 3 groups: <i>group a)</i> SoCSVV; <i>group b)</i> CV with systemic involvement; <i>group c)</i> subgroup of patients of group b with involvement of 3 organs other than the skin. A comparative study between the group a) with the other two groups (b and c) was performed. <h3>Results</h3> <i>Group a)</i> was integrated by 9 patients (7 W/2 M; mean age, 64±16 years). In the <i>group b)</i> 43 patients were included (18 W/25M; mean age, 54±21 years). The underlying conditions were: severe bacterial infections (n=12), hypersensitivity vasculitis with involvement of other organs besides the skin (n=10), HSP (n=9), panarteritis nodosa (n=4), microscopic polyangiitis (n=2), cryoglobulinemia (n=2), malignancy (n=2), SLE (n=1) and Sjögren9s syndrome (n=1). Finally, 7 patients (3 W/4 M; mean age, 50 ± 20 years) were included in <i>group c)</i>. The underlying conditions were: severe bacterial infections (n=3), HSP (n=3) and cryoglobulinemia (n=1). The results of histopathological comparison of <i>group a)</i> with the <i>groups b)</i> and <i>c)</i> are shown in the table. Although no parameter reached statistical significance, in our series we observed that the greater systemic involvement was more frequently associated with tissue neutrophilia, pustular dermatosis and deep involvement of arterioles. By contrast, SoCSVV tend to develop greater tissue eosinophilia and tissue lymphocytosis, whilst the intensity of the inflammatory infiltrate was lower. On the other hand, none of the samples of patients with SoCSVV showed involvement of deep arterioles. <h3>Conclusions</h3> In this series we observed that qualitative and quantitative histological differences were correlated with the degree of systemic involvement. However, these results need to be tested in prospective studies with a larger number of patients. <h3>Acknowledgement</h3> “Fondo de Investigaciones Sanitarias” PI12/00193 (Spain) and RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from “Instituto de Salud Carlos III” (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared
Kinomic Profiling of Pediatric Acute Myeloid Leukemia for Detailed Cellular Insights
Authors: Hasan Mahmud, Pariya Bezrouzi, Arja ter Elst, Frank J.G. Scherpen, Kim R. Kampen, Valerie De Haas, Victor Guryev, Maikel P Peppelenbosch, Frank Johannes, Steven M. Kornblau, Eveline Bont
Journal: Blood (2014)
Secretion and Activity of ADAMTS13 Are Impaired by Cyclosporin A
Authors: Vijaya L. Simhadri, Klilah Hershko, Adam Blaisdell, Andrew Wu, Sandy Tseng, Jordan Newell, Ryan Hunt, JaeWon Choi, Zuben E. Sauna, Richard J. Bram, Anton A. Komar, Chava Kimchi-Sarfaty
Journal: Blood (2012)
Unlike CML Patients, Patients with Gastrointestinal Stromal Tumors (GIST) Treated with Imatinib Do Not Develop Hematopoietic Clonal Cytogenetic Abnormalities.
Authors: Manuel M. Abecasis, Pedro Lage, Maria Salazar, Joao Freire, Antonio Moreira, Margarida Jorge, Helena Alaiz
Journal: Blood (2004)
NIMG-27USING MR PERFUSION TO STRATIFY PATIENTS WITH TREATED HIGH-GRADE GLIOMAS: DOES IT CORRELATE WITH OVERALL SURVIVAL?
Authors: Crystal Fong, Jeffrey Greenspoon, Sameer Parpia, Brian Yemen, Scott Tsai
Journal: Neuro-Oncology (2015)

BACKGROUND: MR perfusion (MRP) is a relatively new technique, which may aid in identifying tumour recurrence in those with radically treated high-grade gliomas (HGG). Salvage therapies can diminish quality of life; therefore, it is imperative to identify those with true recurrence who may benefit from additional treatment. We aim to assess the relationship between MRP and overall survival to establish the role of MRP as a clinical decision-making tool as well as a prognostic assessment tool. METHODS: A retrospective chart review of adult patients with histopathologically confirmed diagnosis of HGG and who have had at least one post-treatment MRP scan between January 2011 and April 2014 was conducted. MRP studies were interpreted by experienced radiologists based on relative cerebral blood volume (rCBV) colour maps. Survival data was collected from medical records and obituary databases. RESULTS: Sixty-one patients (mean age 56 years) with HGG (18 grade III, 43 grade IV) were included in the analysis. An increased survival benefit was observed in patients with negative MRP (median survival = 10 months) compared to those with positive MRP (median survival = 5 months), [hazard ratio (HR) = 2.51; 95% confidence interval (CI): 1.09 to 5.76; p = 0.03]. The adjusted analysis including all pre-selected variables demonstrated a similar relationship between MRP and overall survival [HR = 2.53; 95% CI: 1.05 to 6.14; p = 0.04]. Other independent predictors did not demonstrate a statistically significant association with overall survival. CONCLUSION: Our data suggest that a positive MRP result may signify the presence of highly active tumour and thus significantly lower overall survival. This implicates a prognostic role for the use of serial MRP studies to identify a time point in which tumour recurrence becomes highly aggressive, which can affect treatment determination and, more importantly, aid in clinical decision-making.
Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide
Authors: Zhichu Xiang, Xiaoliang Yang, Junjie Xu, Wenjia Lai, Zihua Wang, Zhiyuan Hu, Jiesheng Tian, Lingling Geng, Qiaojun Fang
Journal: Biomaterials (2016)
Graft Versus Host Disease (GvHD) Is Attenuated By Administration of Pregnancy Specific Glycoproteins through Induction of Immune Tolerance
Authors: Karlie R. Sharma, Shemona Rattila, Patricia Kiesler, Angela Ballesteros, Jian Luo, Sherry Koontz, James Warren, Harry L. Malech, Gabriela Dveksler, Elizabeth M. Kang
Journal: Blood (2015)
Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).
Authors: Xavier Leleu, Benjamin Hebraud, Guillemette Fouquet, Murielle Roussel, Denis Caillot, Marie-Lorraine Chretien, Bertrand Arnulf, Raphael Szalat, Laurent Garderet, Lina Benajiba, Brigitte Pegourie, Caroline Regny, Bruno Royer, Alexis Caulier, Anne-Marie Stoppa, Sylvain Garciaz, Cyrille Touzeau, Jean-Paul Fermand, Thierry Facon, Michel Attal, Philippe Moreau
Journal: Blood (2012)
P209 Specialist respiratory pharmacist case management copd medicines optimisation clinics: implementation and outcomes
Authors: C Jones, R Miller, R Sharkey, A Friel, D Clifford, C Darcy, B Moore, M Hall
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> In line with 'Transforming Your Care' (restructuring of healthcare provision in Northern Ireland) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, this project brought specialist trust pharmacist-led medicines optimisation case management clinics to COPD patients in primary care. The aim of the project was to achieve sustained medicines optimisation with associated improved patient outcomes. <h3>Method</h3> An initial process mapping event resulted in establishing the existing COPD patient pathway between primary and secondary care. This informed the decision to base clinics in GP surgeries where the pharmacist: determined disease stage (GOLD classification); assessed medication adherence; established COPD medication appropriateness; prescribed COPD medications and smoking cessation; determined whether antibiotic prescribing was guideline-informed; and made appropriate referrals to primary and secondary care healthcare professionals. A 30-day telephone follow-up by the pharmacist involved reassessment of adherence, symptom scores and medication appropriateness. COPD exacerbations, antibiotic prescribing and unplanned hospital admissions were further recorded over 12 months. All data were analysed using SPSS Version 22. <h3>Results</h3> Results for a patient cohort seen over four months (n = 360) demonstrated: statistically significant improvements in COPD medication appropriateness and adherence (Wilcoxon Signed Rank Test, p &lt; 0.001, n = 360); improvement in COPD symptoms (MRC Breathlessness and CAT score); and reduced guideline-informed antibiotic prescribing (12 months post baseline review). Projected annual drug cost savings were £235k. Sixty-eight percent of patients had experienced one or more COPD exacerbations over the year prior to clinic attendance reducing to 50% during the 12 months post-intervention. Non-elective COPD-related hospital admissions also decreased (9.2% versus 5.3% over 12 months). <h3>Conclusion</h3> Providing specialist hospital pharmacist COPD clinics in primary care resulted in safe and cost-effective medication use with improved patient outcomes 12 months post review.
A Somatic Mutation in the G6PD Gene in Hematopoietic Cells Causes a Chronic Haemolytic Anemia.
Authors: Loïc Garçon, Gérard Tertian, Audrey Boutron, Françoise Driss, Stéphane Giraudier, William Vainchenker, Michel Goossens, Frederic Galacteros, Gil Tchernia, Claude Préhu
Journal: Blood (2009)
SAT0121 The Effect of Type 2 Diabetes on Disease Activity in Male and Female Rheumatoid Arthritis Patients: Table 1.
Authors: L. Nieuwenhuis, V. Brown, C. Popa, J. Fransen
Journal: Annals of the Rheumatic Diseases (2016)

Background  Rheumatoid arthritis (RA) patients with comorbidities are likely to have higher disease activity (DAS28) scores than patients without comorbidities 1–3 . Diabetes has been recently suggested to associate with higher disease activity in a large group of RA patients 4 ; however, it is still uncertain how baseline diabetes affects RA disease activity and remission percentages in RA 5 . This is important and information might be used to improve treatment strategies.  Objectives  To investigate the effect of having type 2 diabetes on DAS28 scores and RA remission percentages in male and female RA patients during the first year after RA diagnosis.  Methods  Data were retrieved from the prospective Nijmegen Early RA cohort. Patients fulfilled the ACR or ACR-EULAR classification criteria. The course of disease activity (DAS28) over the first year after RA diagnosis was the primary outcome. Secondary outcome was RA remission one year after diagnosis (DAS28 score  6 . Presence of diabetes was defined by physician diagnosis. Statistical analyses comprised mixed linear models and logistic regression. Potential confounders included smoking, BMI, alcohol intake, age, HAQ score and rheumatoid factor at baseline. Gender was treated as effect modifier.  Results  35 (4.2%) out of the 840 included patients had DM2 at baseline. Mean DAS28 values at baseline were 5.33 (SE 0.20) for diabetic and 5.04 (SE 0.05) for non-diabetic patients (p  Conclusions  There was no large influence of having DM on baseline DAS28, response in DAS28 scores and remission percentages during the first year after RA diagnosis; this was the same for male and female patients.  References  Bilecik NA, et al. Int J Clin Exp Med. 2014 Aug 15;7(8):2258–65.  Nakajima A, et al. Clin Rheumatol. 2015 Mar;34(3):441–9.  Tiippana-Kinnunen T, et al. Scand J Rheumatol. 2013;42(6):451–6.  Crepaldi G, et al. PLoS One. 2016 Jan 12;11(1):e0146991.  Kroot EJ, et al. J Rheumatol. 2001 Jul;28(7):1511–7.  Fransen J, et al. Rheumatology (Oxford). 2004 Oct;43(10):1252–5.  Disclosure of Interest  None declared
Small Molecule Inhibitor of Neutrophil Elastase Restores Impaired Production of Human Myeloid Cells Observed in Severe Congenital Neutropenia.
Authors: Andrew A. Aprikyan, Vahagn Makaryan, Qian Si, Kelly Treonze, Nara Markosyan, Paul Finke, Maxim Totrov, Ruben Abagyan, Richard Mumford, David Dale
Journal: Blood (2007)
A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.
Authors: Janice Gabrilove, Ron Paquette, Roger Lyons, Chaudhry Mushtaq, Mikkael Sekeres, Hung Lam, Lyndah Dreiling
Journal: Blood (2005)
Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.
Authors: Lawrence T Goodnough, George Despotis, Peter K Smith, Jerrold Levy, Robert Poston, Mary Short, Govinda Weerakkody, LeRoy Lenarz
Journal: Blood (2010)
Long Term Statin Use and Risk of Multiple Myeloma Among 15.5 Million Taiwanese Adults: A Retrospective Cohort Study
Authors: Brian C.-H. Chiu, Jin-Hua Chen, Yu-Chun Yen, Gregory S. Calip, Chun-Ru Chien, Habibul Ahsan, Ya-Chen T Shih, Kuang-Fu Cheng
Journal: Blood (2015)
OC-055 Blood-Based Biomarkers in the Oesophageal Cancer Model – Results from the PigA Mutant Phenotype Study
Authors: HN Haboubi, L Williams, J Manson, N Al-Mossawi, B Rees, R Lawrence, O Bodger, P Griffiths, C Thornton, GJ Jenkins
Journal: Gut (2016)

<h3>Introduction</h3> Improving our mechanisms of risk stratification of patients with Barrett’s oesophagus (BO) requires easily analysable, cheap and reproducable biomarkers. The PigA mutant phenotype assay is a novel flow cytometric analysis, which can be undertaken using a fingerprick test. The PigA gene codes for GPI-anchors, which tether proteins to the surface of circulating blood cells. Silencing mutations, induced by acid or bile, will therefore result in absence of surface GPI-anchors and negative fluorescence on flow cytometry analysis. Our laboratory has already demonstrated the effects of bile in inducing such "mutant" events in blood based cell lines. <h3>Methods</h3> Here, we investigate the baseline background PigA mutant phenotype frequency in patients with GORD, BO, and those with oesophageal adenocarcinoma (OAC). We recruited 120 patients for analysis of baseline mutant frequency in circulating red blood cells. We correlated these findings with symptoms, diet, lifestyle, endoscopic features and radiological stage. We also undertook Western Blotting analysis of endoscopic biopsies to assess GPI-anchor status in retrieved tissue. <h3>Results</h3> A clear correlation was seen with increased PigA mutant frequency with histological status from healthy patients with GORD to those with OAC, p &lt; 0.01. Older age, smoking status and unhealthy lifestyle (diet measured using the DQS score) all resulted in higher mutant frequencies. Length of Barrett’s and degree of inflammation (LA classification) had no effect, but aspirin use appeared to be protective and resulted in lower mutant frequencies (p &lt; 0.01). Evaluation of patients with cancer (n = 15) found that PigA mutant frequency increased with increasing lymph node involvement and metastasic spread (both p &lt; 0.001). Finally western blotting of crude protein extracted from oesophageal biopsies revealed a reduction in GPI-anchor levels from normal squamous tissue, through to cancer, thus corroborating our results above. <h3>Conclusion</h3> We have developed a blood-based biomarker assay, which can potentially stratify patients’ underlying genomic instability by indirectly measuring GPI-anchor status on circulating blood cells. We have also demonstrated the potential onco-protective effects of aspirin in these patients. The mechanisms behind these observations remain unclear, but western blot analysis suggests mutation may occur in the distal oesophagus where circulating blood cells are exposured to mutagenic chemicals such as bile and acid. Further evaluation in other cancer models as well as a wider cohort of non-cancer patients (to evaluate lifetyle) will establish how useful the assay may be outside of the Barrett’s model. <h3>Disclosure of Interest</h3> None Declared
STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.
Authors: Sirpa Leppä, Minna Taskinen, Antti Sommarhem, Erkki Elonen, Matti Nykter, Outi Monni, Tuomo Timonen, Sampsa Hautaniemi, Marja-Liisa Karjalainen-Lindsberg, Seppo Meri
Journal: Blood (2007)
Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)
Authors: Issa F. Khouri, Rima M Saliba, Zijun Y. Xu-Monette, Martin Korbling, Gabriela Rondon, Rosamar Valverde, Amin M. Alousi, Paolo Anderlini, Sairah Ahmed, Stefan O Ciurea, Luis Fayad, Betul Oran, Simrit Parmar, Uday R. Popat, Jason R. Westin, Francesco Turturro, L. Jeffrey Medeiros, Alison M Gulbis, Ken H. Young
Journal: Blood (2014)
Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas
Authors: Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Eliana Valentina Liardo, Stefano Luminari, Francesco Merli, Antonio Lazzaro, Santo Neri, Angelo Michele Carella, Alberto Fragasso, Simona Falorio, Gabriele Buda, Pellegrino Musto, Matteo Dell’Olio, Luca Baldini
Journal: Blood (2010)
AB1014 Comparison between Arashi Score and Modified Total Sharp Score in The Evaluation of Large Joints Destruction in Patients with Rheumatoid Arthritis under Disease Control of Biologic Disease Modifying Anti-Rheumatic Drugs
Authors: K. Hashizume, K. Nishida, Y. Nasu, R. Nakahara, T. Machida, M. Horita, A. Takeshita, D. Kaneda, M. Natsumeda, K. Ezawa, T. Ozaki
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Treatment of rheumatoid arthritis (RA) has improved over the past decade with the modification of treatment strategy and recent application of biologic agents (Bio). It has been revealed that the treatment by Bio achieved not only improvement of clinical symptom, but also inhibition of the progression of joint destruction in small joints of hand and foot. However, there are little evidences of inhibition of the progression of the large joint destruction with the treatment by Bio. ARASHI score, is composed of ARASHI Status Score (ASS) and ARASHI Change Score (ACS), and have been newly developed to evaluate the progression of the large joint destruction as well as remodeling<sup>1)</sup> <h3>Objectives</h3> We aimed to investigate the correlation among the ARASHI score, modified total sharp score (mTSS), and other clinical parameters, and to clarify the patients9 parameters leading to large joint destructions in patients with RA under disease control by Bio. <h3>Methods</h3> 75 patients with RA under disease control by Bio were available for the current study. Average patients9 age, disease duration, and follow-up periods were 62.6 (years old), 11.7 (year), and 21.8 (month), respectively. They were examined for serum level of C-reactive protein (CRP), mHAQ, DAS28-CRP, SDAI, CDAI, mTSS, and ASS at the beginning of the study. The amount of change of CRP, mHAQ, DAS28-CRP, SDAI, CDAI, and mTSS at the final follow-up were defined as ΔCRP, ΔmHAQ, ΔDAS28-CRP, ΔSDAI, ΔCDAI, and ΔmTSS, respectively. Statistical analysis was performed by Spearman9s correlation co-efficient. <h3>Results</h3> Average ΔCRP, ΔmHAQ, ΔDAS28-CRP, ΔSDAI, ΔCDAI, ΔmTSS, and ACS were 0.01, -0.02, -0.28, -2.62, -2.64, and 0.03, respectively. There was no significant correlation between the ACS and ΔmTSS. There were no significant correlations between ΔmTSS and other clinical parameters, whereas ACS was significantly correlated with ΔCRP (r=0.39), ΔmHAQ (r=0.28), ΔDAS28-CRP (r=0.39), ΔSDAI (r=0.35), and ΔCDAI (r=0.32). <h3>Conclusions</h3> The correlation between the destruction of small joints of hands and feet and the disease activity was not seen among the current patients group with long-standing disease. In contrast, our results suggested that sufficient suppression of the disease activity is important to prevent the progression of large joint destruction among long-standing RA patients under control by Bio. <h3>References</h3> Kaneko A, et al., Mod Rheumatol. 2013;23:1053–62 <h3>Disclosure of Interest</h3> None declared
Defective Modification of Mannose Residues by Terminal Phosphoethanolamine Underlies Inherited GPI Deficiency.
Authors: A. M. Almeida, P. Hillmen, S. J. Richards, D. H. Crawford, A. Baker, M. A. Ferguson, I. A. Roberts, D. M. Layton, A. Karadimitris
Journal: Blood (2005)
From POEM to POET: Applications and perspectives for submucosal tunnel endoscopy
Authors: Philip Chiu, Haruhiro Inoue, Thomas Rösch
Journal: Endoscopy (2016)

Recent advances in submucosal endoscopy have unlocked a new horizon for potential development in diagnostic and therapeutic endoscopy. Increasing evidence has demonstrated that peroral endoscopic myotomy (POEM) is not only clinically feasible and safe, but also has excellent results in symptomatic relief of achalasia. The success of submucosal endoscopy in performance of tumor resection has confirmed the potential of this new area in diagnostic and therapeutic endoscopy. This article reviews the current applications and evidence, from POEM to peroral endoscopic tunnel resection (POET), while exploring the possible future clinical applications in this field.
A Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma
Authors: Arnaud Jaccard, Nathalie Gachard, Paul Coppo, Franck Morschhauser, Lionel Galicier, Loic Ysebaert, Philippe Lenain, Bernadette Corront, Felipe Suarez, Jean Feuillard, Philippe Gaulard, Dominique Bordessoule, Olivier Hermine
Journal: Blood (2008)
Febuxostat Pharmacokinetic/Pharmacodynamic Bridging from Adults to Pediatrics for Effective Prophylaxis of Tumor Lysis Syndrome: From Florence to Floret Study
Authors: Michele Spina, Paolo Mazzei, Simone Baldini, Marta Pedretti, Enrica Mezzalana, Mariagiuseppa Matera, Silvia Manunta, Giulia Calamai, Alessandra Scordari, Simona Scartoni, Angela Capriati, Cecilia Simonelli, Franco Locatelli
Journal: Blood (2015)
IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.
Authors: Lenka V. Hurton, Harjeet Singh, Simon Olivares, Sonny O. Ang, Susan Staba Kelly, Partow Kebriaei, Dean A. Lee, Richard E. Champlin, Laurence J.N. Cooper
Journal: Blood (2009)
Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis
Authors: Uday Deotare, Marwan Shaheen, Joseph M. Brandwein, Bethany Gill, Suzanne Kamel-Reid, Karen W.L. Yee, Anna Rydlewski, Andrzej Lutynski, Amr Rostom, Aaron D Schimmer, Mark D. Minden, Vikas Gupta, Matthew D. Seftel, Naheed Alam, Andre C Schuh
Journal: Blood (2014)
Control Of Allograft Rejection With Mitomycin C Incubated Blood Cells
Authors: Johann Greil, Christian Kleist, Elisabeth Mohr, Flavius Sandra-Petrescu, Lucian Jiga, Laura Dittmar, Venkata Satagopam, Haydar Demirdizen, Michael Hundemer, Luis Becker, Peter Lang, Gerhard Opelz, Peter Terness
Journal: Blood (2013)
P0241 : CD40/CD40Ligand interaction between tumor lysate-pulsed dendritic cells induces a Th1-environment and enhances the cytotoxic activity of immunologic effector cells towards human hepatocellular carcinoma and cholangiocellular carcinoma cells
Authors: A. Vogt, R.M. Hillebrand, E. Raskopf, I.G. Schmidt-Wolf, C.P. Strassburg, M.A. Gonzalez-Carmona
Journal: Journal of Hepatology (2015)